Semaglutide, which is also available under the brand names Ozempic and Rybelsus, is a GLP-1 receptor agonist that has been shown to help people with type 2 diabetes lose weight, lower glucose levels, and protect against diabetes-related heart complications
The recognition of the contribution of other hormones in the incretin system, with pleiotropic actions, has led to the development of dual agonists, which can maximise metabolic benefits with a lower potential for side-effects
KLOW's added KPV component addresses this directly
5,11 Figure 1: GLP-1 Timeline
It is shown to be increasing dopamine-B-hydroxylase levels, decreasing extracellular dopamine release, increasing DAT surface expression, increasing dopamine turnover, and suppressing projections to NAc, GLP-1R agonists might be decreasing palatable food or drug-induced phasic dopaminergic signaling in reward-related areas and therefore decreasing conditioned consummatory behavior
Sci Rep (2017) 7(1):8933